Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

Background: Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water and low bioavailability. Objective:To increase the solubility of PM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zejiang, Wen, Jiaolin, Xu, Yaohui, Pei, Heying, Li, Dan, Tang, Minghai, Bai, Peng, He, Jun, Yang, Zhuang, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903780/
https://www.ncbi.nlm.nih.gov/pubmed/35243950
http://dx.doi.org/10.1080/07853890.2022.2045347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903780/
https://www.ncbi.nlm.nih.gov/pubmed/35243950
http://dx.doi.org/10.1080/07853890.2022.2045347

Ejemplares similares